CHICAGO, Dec. 24, 2014 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VNDA, CAR ...
Abbott Laboratories ABT has agreed to divest two medical device businesses in order to settle Federal Trade ... Cap Pharmaceuticals industry in the year-to-date period. In fact, the stock has lost 14.9% during this period, compared with …
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please …
Vanda Pharmaceuticals Inc : Vanda pharmaceuticals reports second quarter 2016 financial results . Vanda reiterates 2016 net product sales guidance of $143 million to $153 million . Qtrly loss per share $0.11; revenue $36.03 million . Says …
The Indonesia stock market has finished lower in back-to-back trading days, sliding 20 points or 0.3 percent along the way. The Jakarta Composite Index remains just above the 6,615-point plateau and it may see additional consolidation on …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VNDA at https://www.zacks.com/ap/VNDA
velusetrag (a selective 5-HT4 receptor agonist), for the treatment of symptoms associated with idiopathic and diabetic gastroparesis. Theravance's year-to-date share price movement shows that the stock has outperformed the Zacks …
Amphastar’s one-month share price movement shows that the stock has underperformed the Zacks classified ... Cambrex Corporation CBM and Vanda Pharmaceuticals Inc. VNDA. Each of these stocks sports a Zacks Rank #1 (Strong Buy). …
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VNDA at https://www.zacks.com/ap/VNDA